Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome

Authors: Elsa G. Shapiro, Chester B. Whitley, Julie B. Eisengart

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Hurler syndrome (MPS IH), the severe, neurodegenerative form of type one mucopolysaccharidosis, is associated with rapid neurocognitive decline during toddlerhood and multi-system dysfunction. It is now standardly treated with hematopoietic cell transplantation (HCT), which halts accumulating disease pathology and prevents early death. While norm-based data on developmental functioning in untreated children have previously demonstrated neurocognitive decline, advances in methodology for understanding the cognitive functioning of children with neurodegenerative diseases have highlighted that the previous choice of scores to report results was not ideal. Specifically, the lowest possible norm-based score is 50, which obscures the complete range of cognitive functioning at more advanced stages of neurodeterioration. To a set of cognitive data collected on a sample of untreated children, we applied a modern method of score analysis, calculating a developmental quotient based on age equivalent scores, to reveal the full range of cognitive functioning beneath this cutoff of 50, uncovering new information about the rapidity of decline and the profound impairment in these children.

Results

Among 39 observations for 32 patients with untreated Hurler syndrome, the full array of cognitive functioning below 50 includes many children in the severely to profoundly impaired range. The loss of skills per time unit was 14 points between age 1 and 2. There was a very large range of developmental quotients corresponding to the norm-based cutoff of 50.

Conclusions

This report enables clarification of functioning at levels that extend beneath the floor of 50 in previous work. At the dawn of newborn screening and amidst a proliferation of new therapies for MPS I, these data can provide crucial benchmark information for developing treatments, particularly for areas of the world where transplant may not be available.
Footnotes
1
William Krivit, MD PhD; Deceased, December 8, 2005. Principal investigator of the NIH grant (#NS 29099) that recruited many of these patients; he and Dr. Whitley screened for and performed the initial bone marrow transplants at the University of Minnesota.
 
2
Either by author (ES) or by Pi-Nian Chang, Ph.D., now retired.
 
Literature
1.
go back to reference Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, Yund B, Orchard PJ, Eisengart J, Niklason GR. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116:61–8.CrossRefPubMedPubMedCentral Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, Yund B, Orchard PJ, Eisengart J, Niklason GR. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116:61–8.CrossRefPubMedPubMedCentral
2.
go back to reference Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164–72.CrossRefPubMed Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164–72.CrossRefPubMed
3.
go back to reference Poe MD, Chagnon SL, Escolar ML. Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol. 2014;76:747–53.CrossRefPubMed Poe MD, Chagnon SL, Escolar ML. Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol. 2014;76:747–53.CrossRefPubMed
4.
go back to reference Kunin-Batson A, Shapiro E, Rudser K, Lavery C, Bjoraker K, Jones S, Wynn R, Vellodi A, Tolar J, Orchard P. Long-term cognitive and functional outcomes in children with Mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation J Inherit Metab Dis Rep. 2016;29:1–8. Kunin-Batson A, Shapiro E, Rudser K, Lavery C, Bjoraker K, Jones S, Wynn R, Vellodi A, Tolar J, Orchard P. Long-term cognitive and functional outcomes in children with Mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation J Inherit Metab Dis Rep. 2016;29:1–8.
5.
go back to reference Clarke LA, Atherton AM, Burton BK, Day-Salvatore DL, Kaplan P, Leslie ND, Scott CR, Stockton DW, Thomas JA, Muenzer J. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J Pediatr. 2017;182:363–70.CrossRefPubMed Clarke LA, Atherton AM, Burton BK, Day-Salvatore DL, Kaplan P, Leslie ND, Scott CR, Stockton DW, Thomas JA, Muenzer J. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J Pediatr. 2017;182:363–70.CrossRefPubMed
6.
go back to reference Grosse SD, Lam WK, Wiggins LD, Kemper AR. Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1. Genet Med. 2017;19:975–82. Grosse SD, Lam WK, Wiggins LD, Kemper AR. Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1. Genet Med. 2017;19:975–82.
8.
go back to reference Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999;12:167–76.CrossRefPubMed Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999;12:167–76.CrossRefPubMed
9.
go back to reference Janzen D, Delaney K, Shapiro E. Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: a review of the literature. Mol Genet Metab. 2017;121:57-69. Janzen D, Delaney K, Shapiro E. Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: a review of the literature. Mol Genet Metab. 2017;121:57-69.
10.
go back to reference Bayley N. Manual for the Bayley scales of infant development. New York: Psychological Corporation; 1969. Bayley N. Manual for the Bayley scales of infant development. New York: Psychological Corporation; 1969.
11.
go back to reference Bayley N. Manual for the Bayley scales of infant development (2nd Ed.). San Antonio, TX: Psychological Corporation; 1993. Bayley N. Manual for the Bayley scales of infant development (2nd Ed.). San Antonio, TX: Psychological Corporation; 1993.
12.
go back to reference Ziegler R, Shapiro E. Metabolic and neurodegenerative diseases across the life span principles and practice of lifespan developmental neuropsychology. New York: Cambridge University Press; 2007. p. 427–48. Ziegler R, Shapiro E. Metabolic and neurodegenerative diseases across the life span principles and practice of lifespan developmental neuropsychology. New York: Cambridge University Press; 2007. p. 427–48.
13.
go back to reference Peters C, Balthazor M, Shapiro E, King R, Kollman C, Hegland J, Henslee-Downey J, Trigg M, Cowan M, Sanders J. Outcome of unrelated donor bone marrow transplantation in 40 children with hurler syndrome. Blood. 1996;87:4894.PubMed Peters C, Balthazor M, Shapiro E, King R, Kollman C, Hegland J, Henslee-Downey J, Trigg M, Cowan M, Sanders J. Outcome of unrelated donor bone marrow transplantation in 40 children with hurler syndrome. Blood. 1996;87:4894.PubMed
14.
go back to reference Peters C, Shapiro E, Anderson J, Henslee-Downey P, Klemperer M, Cowan M, Saunders E, deAlarcon P, Twist C, Nachman J. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood. 1998;91:2601.PubMed Peters C, Shapiro E, Anderson J, Henslee-Downey P, Klemperer M, Cowan M, Saunders E, deAlarcon P, Twist C, Nachman J. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood. 1998;91:2601.PubMed
15.
go back to reference Delaney KA, Rudser KR, Yund BD, Whitley CB, Haslett PA, Shapiro EG. Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome, JIMD reports. 2014;13:129–37. Delaney KA, Rudser KR, Yund BD, Whitley CB, Haslett PA, Shapiro EG. Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome, JIMD reports. 2014;13:129–37.
16.
go back to reference Shapiro EG, Nestrasil I, Delaney KA, Rudser K, Kovac V, Nair N, Richard CW, Haslett P, Whitley CB. A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr. 2016;170:278–87. e274CrossRefPubMedPubMedCentral Shapiro EG, Nestrasil I, Delaney KA, Rudser K, Kovac V, Nair N, Richard CW, Haslett P, Whitley CB. A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr. 2016;170:278–87. e274CrossRefPubMedPubMedCentral
17.
go back to reference Shapiro E, Bernstein J, Adams HR, Barbier AJ, Buracchio T, Como P, Delaney KA, Eichler F, Goldsmith JC, Hogan M. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Mol Genet Metab. 2016;118:65–9.CrossRefPubMedPubMedCentral Shapiro E, Bernstein J, Adams HR, Barbier AJ, Buracchio T, Como P, Delaney KA, Eichler F, Goldsmith JC, Hogan M. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Mol Genet Metab. 2016;118:65–9.CrossRefPubMedPubMedCentral
18.
go back to reference van der Lee JH, Morton J, Adams HR, Clarke L, Ebbink BJ, Escolar ML, Giugliani R, Harmatz P, Hogan M, Jones S, Kearney S, Muenzer J, Rust S, Semrud-Clikeman M, Wijburg F, Yu Z, Janzen D, Shapiro E. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure. Mol Genet Metab. 2017;121:70–79. van der Lee JH, Morton J, Adams HR, Clarke L, Ebbink BJ, Escolar ML, Giugliani R, Harmatz P, Hogan M, Jones S, Kearney S, Muenzer J, Rust S, Semrud-Clikeman M, Wijburg F, Yu Z, Janzen D, Shapiro E. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure. Mol Genet Metab. 2017;121:70–79.
19.
go back to reference Martin HR, Poe MD, Reinhartsen D, Pretzel RE, Roush J, Rosenberg A, Dusing SC, Escolar ML. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr. 2008;97:69–75.CrossRefPubMed Martin HR, Poe MD, Reinhartsen D, Pretzel RE, Roush J, Rosenberg A, Dusing SC, Escolar ML. Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective. Acta Paediatr. 2008;97:69–75.CrossRefPubMed
20.
go back to reference Dornelles AD, de Camargo Pinto LL, de Paula AC, Steiner CE, Lourenço CM, Kim C, Horovitz DDG, Ribeiro EM, Valadares ER, Goulart I. Enzyme replacement therapy for Mucopolysaccharidosis type I among patients followed within the MPS Brazil network. Genet Mol Biol. 2014;37:23–9.CrossRefPubMed Dornelles AD, de Camargo Pinto LL, de Paula AC, Steiner CE, Lourenço CM, Kim C, Horovitz DDG, Ribeiro EM, Valadares ER, Goulart I. Enzyme replacement therapy for Mucopolysaccharidosis type I among patients followed within the MPS Brazil network. Genet Mol Biol. 2014;37:23–9.CrossRefPubMed
21.
go back to reference da Silva Franco JF, El Dib R, Agarwal A, Soares D, Milhan NVM, Albano LMJ, Kim CA. Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: results from a single-center case series study. Intractable Rare Dis Res. 2017;6:183–90.CrossRef da Silva Franco JF, El Dib R, Agarwal A, Soares D, Milhan NVM, Albano LMJ, Kim CA. Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: results from a single-center case series study. Intractable Rare Dis Res. 2017;6:183–90.CrossRef
22.
go back to reference Eisengart JB, Jarnes J, Ahmed A, Nestrasil I, Ziegler R, Delaney K, Shapiro E, Whitley C. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Mol Genet Metab Rep. 2017;13:64–8.CrossRefPubMedPubMedCentral Eisengart JB, Jarnes J, Ahmed A, Nestrasil I, Ziegler R, Delaney K, Shapiro E, Whitley C. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Mol Genet Metab Rep. 2017;13:64–8.CrossRefPubMedPubMedCentral
23.
go back to reference Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, Van der Ploeg A, Mercer J, Jones S, Mengel KE, Gökce S, Guffon N, Giugliani R, de Souza CFM, Shapiro EG, Whitley CB. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. 2018. https://doi.org/10.1038/gim.2018.29. Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, Van der Ploeg A, Mercer J, Jones S, Mengel KE, Gökce S, Guffon N, Giugliani R, de Souza CFM, Shapiro EG, Whitley CB. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. 2018. https://​doi.​org/​10.​1038/​gim.​2018.​29.
24.
go back to reference Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type a. J Inherit Metab Dis. 2014;37:431–7.CrossRefPubMed Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type a. J Inherit Metab Dis. 2014;37:431–7.CrossRefPubMed
25.
go back to reference Ahmed A, Rudser K, Kunin-Batson A, Delaney K, Whitley C, Shapiro E. Mucopolysaccharidosis (MPS) physical symptom score: development, reliability, and validity, JIMD reports. 2015;26:61–8. Ahmed A, Rudser K, Kunin-Batson A, Delaney K, Whitley C, Shapiro E. Mucopolysaccharidosis (MPS) physical symptom score: development, reliability, and validity, JIMD reports. 2015;26:61–8.
26.
go back to reference Ahmed A, Shapiro E, Rudser K, Kunin-Batson A, King K, Whitley CB. Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Mol Genet Metab Rep. 2016;7:27–31. Ahmed A, Shapiro E, Rudser K, Kunin-Batson A, King K, Whitley CB. Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Mol Genet Metab Rep. 2016;7:27–31.
27.
go back to reference Escolar ML, Aldenhoven M. Leukodystrophies and lysosomal storage disorders. In: Boelens JJ, Wynn R, editors. Stem cell biology and regenerative medicine. New York: Springer; 2013. p. 63–125. Escolar ML, Aldenhoven M. Leukodystrophies and lysosomal storage disorders. In: Boelens JJ, Wynn R, editors. Stem cell biology and regenerative medicine. New York: Springer; 2013. p. 63–125.
28.
go back to reference Polgreen L, Tolar J, Plog M, Himes J, Orchard P, Whitley C, Miller B, Petryk A. Growth and endocrine function in patients with hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1005–11.CrossRefPubMed Polgreen L, Tolar J, Plog M, Himes J, Orchard P, Whitley C, Miller B, Petryk A. Growth and endocrine function in patients with hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1005–11.CrossRefPubMed
29.
go back to reference Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM, Giugliani R. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183–97.CrossRefPubMedPubMedCentral Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM, Giugliani R. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183–97.CrossRefPubMedPubMedCentral
Metadata
Title
Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome
Authors
Elsa G. Shapiro
Chester B. Whitley
Julie B. Eisengart
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0817-3

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue